ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

▴ ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe
This authorization represents the first time people living with HIV in Europe may be able to receive a long-acting injectable treatment that removes the need to take daily oral tablets

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, announced the authorisation of Vocabria (cabotegravir injection and tablets) in combination with Janssen Pharmaceutical Companies of Johnson & Johnson’s Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets), in the European Union, for the treatment of HIV-1 infection in adults who are virologically suppressed.

Cabotegravir injection is indicated, in combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. This authorisation represents the first time people living with HIV in Europe may be able to receive a long-acting injectable treatment that removes the need to take daily oral tablets, following the oral initiation phase.

Tags : #LatestPharmaNewsDec21 #LatestGskNewsDec21 #TreatmentforHIV

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Can Just Three Days of Junk Food Harm Your Brain? Science Says YesMarch 08, 2025
Your Night Shifts Might Be Damaging Your DNA: Here’s How to Fight BackMarch 08, 2025
India’s Women: Empowered on Paper, Struggling in RealityMarch 08, 2025
NephroPlus to Launch Nationwide Free Health Screening Campaign to Commemorate World Kidney Day 2025 March 07, 2025
Skinny But Sick? Is our Body Mass Index Misleading UsMarch 07, 2025
Scientists Stumble Upon a Cancer-Fighting Secret Hidden in Your Medicine CabinetMarch 07, 2025
The Bitter Truth About Butter: Is our Favourite Spread Cutting our Life Short?March 07, 2025
March 07, 2025
March 06, 2025
University of Leeds scientists offer hope for people facing chronic painMarch 06, 2025
Impact of excessive use of gym supplements on gym enthusiastsMarch 06, 2025
Himalaya Wellness Launches the Himalaya 1derwoman Project, Inspiring Young Girls to Be #1March 06, 2025
Gujarat’s Medical Education Expansion: A Game Changer or Just Numbers on Paper?March 06, 2025
440 Million at Risk: Is India Becoming the Next Obesity Capital?March 06, 2025
Mystery Illness Claims Lives in Chhattisgarh: Is It a Health Crisis in the Making?March 06, 2025
Rising obesity rate in kidsMarch 05, 2025
India’s Clinical Trials Market: Can We Leap from Underdog to Global Leader?March 05, 2025
India’s GBS Outbreak: Is Contaminated Water Fueling a Paralysis Crisis? March 05, 2025
3-Day-Old Baby Born with One Lung Gets a New Lease on Life at SRM Global Hospitals after Rare SurgeryMarch 04, 2025
3-Day-Old Baby Born with One Lung Gets a New Lease on Life at SRM Global Hospitals after Rare SurgeryMarch 04, 2025